Daewoong Pharmaceutical, First in Pharmaceutical Industry to Simultaneously Obtain International Certifications for Information Security and Personal Data Protection

Obtained ISO27001 Certification for Pharmaceutical Manufacturing, Production, and R&D
Simultaneously Acquired ISO27701 Certification for Clinical Trial Personal Data

On the 23rd, Lee Chang-jae, CEO of Daewoong Pharmaceutical (left), and Lim Sung-hwan, CEO of BSI Group Korea, are taking a commemorative photo at the ISO27001 and ISO2770 certification award ceremony.

[Asia Economy Reporter Lee Gwan-joo] Daewoong Pharmaceutical announced on the 24th that it has simultaneously obtained the international standard information security certification ISO27001 and the international standard personal information protection certification ISO27701, becoming the first in the pharmaceutical industry to do so.

ISO27001 is a global standard for information security management systems, verifying whether a company systematically establishes and documents processes to protect the confidentiality, integrity, and availability of information assets and continuously operates and manages them. The scope of ISO27001 certification obtained by Daewoong Pharmaceutical includes the manufacturing and production of pharmaceuticals and research and development operations, incorporating the production technology of its botulinum toxin preparation (Nabota), designated as a national core technology. The sites covered by the certification scope are the production plants located in Osong and Hyangnam, and the research institute located in Yongin.

ISO27701, an extension of ISO27001, is a global standard for personal information protection management systems, verifying whether a company complies with requirements for personal information protection. The scope of ISO27701 certification obtained by Daewoong Pharmaceutical covers personal information related to clinical trials in the manufacturing, production, and research fields.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “Through this simultaneous certification, we have succeeded in establishing a global-level information security and personal information risk management system and creating a safe environment for pharmaceutical manufacturing, production, and research and development.” He added, “We expect that these efforts will not only meet the demands and expectations of domestic and international partners but also contribute to enhancing the company’s external credibility.”

This content was produced with the assistance of AI translation services.